Product Description
Cannabinol is a cannabinoid isolated from the plant Cannabis that is a metabolite of tetrahydrocannabinol (THC), with potential immunosuppressive and anti-inflammatory activities. Cannabinol preferentially binds to the cannabinoid G-protein coupled receptor CB2, which is mainly expressed on a variety of immune cells, such as T-cells, B-cells, macrophages and dendritic cells. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Cannabinol)
Mechanisms of Action: CB Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous,Oral,Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: InMed Pharmaceuticals
Company Location: VANCOUVER A1 V6C 1B4
Company CEO: Eric A. Adams
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, France, Germany, Greece, Israel, Italy
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Epidermolysis Bullosa Dystrophica|Epidermolysis Bullosa Simplex|Epidermolysis Bullosa, Junctional|Insomnia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CUPID | P2 |
Completed |
Insomnia |
2023-08-29 |
|
| 755-201-EB | P2 |
Completed |
Epidermolysis Bullosa, Junctional|Epidermolysis Bullosa Dystrophica|Epidermolysis Bullosa Simplex |
2023-04-03 |
24% |
| 755-201-EB | P2 |
Completed |
Epidermolysis Bullosa, Junctional|Epidermolysis Bullosa Dystrophica|Epidermolysis Bullosa Simplex |
2023-04-03 |
24% |